Vertebrobasilar dolichoectasia(VBD),a rare posterior circulation vascular variant disease,is an important risk factor for many acute cerebrovascular diseases.An insufficient understanding of VBD often leads to misdiag...Vertebrobasilar dolichoectasia(VBD),a rare posterior circulation vascular variant disease,is an important risk factor for many acute cerebrovascular diseases.An insufficient understanding of VBD often leads to misdiagnose.Two cases of VBD that were initially diagnosed as posterior circulation watershed infarction are reported here.Absence of common causes of stroke including hypoperfusion,blood system diseases,carotid and aortic dissection,and eosinophil elevation,the symptoms of the 2 patients met the diagnostic criteria of VBD.Both patients displayed symptoms that were in line with the Traditional Chinese Medicine(TCM)syndrome pattern of"Qi deficiency and blood stasis".Accordingly,they were comprehensively treated with Supplementing Qi and activating blood circulation method.The clinical manifestations of the 2 patients were remarkably improved and no recurrence of watershed infarction was found in a 1-year follow-up.A detailed medical history and laboratory examination are capable of improving diagnostic accuracy of VBD.TCM treatment based on syndrome identification might be a promising candidate for VBD management.展开更多
目的观察疏风活血法治疗糖尿病肾病(DN)A2期风邪证的临床效果。方法筛选60例患者,随机分为对照组及治疗组,各30例。两组患者均给予基础西医治疗,对照组在此基础上给予缬沙坦胶囊口服,治疗组给予缬沙坦胶囊口服+疏风活肾颗粒剂治疗。观...目的观察疏风活血法治疗糖尿病肾病(DN)A2期风邪证的临床效果。方法筛选60例患者,随机分为对照组及治疗组,各30例。两组患者均给予基础西医治疗,对照组在此基础上给予缬沙坦胶囊口服,治疗组给予缬沙坦胶囊口服+疏风活肾颗粒剂治疗。观察治疗前后两组尿微量白蛋白(mALB)、24 h尿蛋白定量(24 h UP)、血浆胱抑素-C(Cys-C)、肾小球滤过率(eGFR)的改善情况及临床疗效。结果治疗组的总有效率为86.7%(26/30),高于对照组的63.3%(19/30)(P<0.05)。治疗后,治疗组中医证候总积分优于对照组(P<0.05);两组患者mALB、24 h UP、Cys-C、eGFR显著改善,且治疗组各指标改善情况均优于对照组(P<0.05)。结论在常规西医治疗方法的基础上应用疏风活血方治疗DN A2期风邪证,对于进一步改善患者肾功能具有重要作用。展开更多
Objective： To investigate the efficacy and safety of the Chinese herbal therapeutic regimen of activating blood circulation （TRABC） in treatment of hypertensive intracerebral hemorrhage （HICH）. Methods： This was...Objective： To investigate the efficacy and safety of the Chinese herbal therapeutic regimen of activating blood circulation （TRABC） in treatment of hypertensive intracerebral hemorrhage （HICH）. Methods： This was a multi-center prospective randomized open-label blinded-endpoint （PROBE） trial with HICH admitted to 12 hospitals. Totally 240 participants were randomized to the treatment group treated with TRABC in addition to conventional Western treatment or the control group with conventional Western treatment equally for 3 months. Primary outcome was degree of disability as measured by modified Rankin Scale （mRS）. Secondary outcomes were the absorption of hematoma and edema, National Institutes of Health Stroke Scale （NIHSS） scores and patient-reported outcome measures for stroke and Barthel activities of daily living index. Adverse events and mortality were also recorded. Results： After 3 months of treatment, the rate of mRS 0-1 and mRS 0-2 in the treatment group was 72.5% and 80.4%, respectively, and in the control group 48.1% and 63.9%, respectively, with a significant difference between groups （P〈0.01）. Hematoma volume decreased significantly at day 7 of treatment in the treatment group than the control group （P=0.038）. Average Barthel scores in the treatment group after treatment was 89.11 ＋ 19.93, and in the control group 82.18 ＋ 24.02 （P=0.003）. NIHSS scores of the two groups after treatment decreased significantly compared with before treatment （P=0.001）. Patient-reported outcomes in the treatment group were lower than the control group at day 21 and 3 months of treatment （P〈0.05）. There were 4 deaths, 2 in each group, and 11 adverse events, 6 in the treatment group and 5 in the control group. Conclusion： The integrative therapy combined TRABC with conventional Western treatment for HICH could promote hematoma absorption thus minimize neurologic impairment, without increasing intracerebral hematoma expansion and re-bleeding.展开更多
基金the 2019 Major Difficult Diseases Clinical Collaboration Capacity Building Project of Traditional Chinese and Western Medicine-cerebral Infarction(No.YW082)。
文摘Vertebrobasilar dolichoectasia(VBD),a rare posterior circulation vascular variant disease,is an important risk factor for many acute cerebrovascular diseases.An insufficient understanding of VBD often leads to misdiagnose.Two cases of VBD that were initially diagnosed as posterior circulation watershed infarction are reported here.Absence of common causes of stroke including hypoperfusion,blood system diseases,carotid and aortic dissection,and eosinophil elevation,the symptoms of the 2 patients met the diagnostic criteria of VBD.Both patients displayed symptoms that were in line with the Traditional Chinese Medicine(TCM)syndrome pattern of"Qi deficiency and blood stasis".Accordingly,they were comprehensively treated with Supplementing Qi and activating blood circulation method.The clinical manifestations of the 2 patients were remarkably improved and no recurrence of watershed infarction was found in a 1-year follow-up.A detailed medical history and laboratory examination are capable of improving diagnostic accuracy of VBD.TCM treatment based on syndrome identification might be a promising candidate for VBD management.
文摘目的观察疏风活血法治疗糖尿病肾病(DN)A2期风邪证的临床效果。方法筛选60例患者,随机分为对照组及治疗组,各30例。两组患者均给予基础西医治疗,对照组在此基础上给予缬沙坦胶囊口服,治疗组给予缬沙坦胶囊口服+疏风活肾颗粒剂治疗。观察治疗前后两组尿微量白蛋白(mALB)、24 h尿蛋白定量(24 h UP)、血浆胱抑素-C(Cys-C)、肾小球滤过率(eGFR)的改善情况及临床疗效。结果治疗组的总有效率为86.7%(26/30),高于对照组的63.3%(19/30)(P<0.05)。治疗后,治疗组中医证候总积分优于对照组(P<0.05);两组患者mALB、24 h UP、Cys-C、eGFR显著改善,且治疗组各指标改善情况均优于对照组(P<0.05)。结论在常规西医治疗方法的基础上应用疏风活血方治疗DN A2期风邪证,对于进一步改善患者肾功能具有重要作用。
基金Supported by the Beijing Committee on Science and Technology,Project on Research on Two Standards of Traditional Chinese Medicine Treatment for Stroke(No.D101107049310003)
文摘Objective： To investigate the efficacy and safety of the Chinese herbal therapeutic regimen of activating blood circulation （TRABC） in treatment of hypertensive intracerebral hemorrhage （HICH）. Methods： This was a multi-center prospective randomized open-label blinded-endpoint （PROBE） trial with HICH admitted to 12 hospitals. Totally 240 participants were randomized to the treatment group treated with TRABC in addition to conventional Western treatment or the control group with conventional Western treatment equally for 3 months. Primary outcome was degree of disability as measured by modified Rankin Scale （mRS）. Secondary outcomes were the absorption of hematoma and edema, National Institutes of Health Stroke Scale （NIHSS） scores and patient-reported outcome measures for stroke and Barthel activities of daily living index. Adverse events and mortality were also recorded. Results： After 3 months of treatment, the rate of mRS 0-1 and mRS 0-2 in the treatment group was 72.5% and 80.4%, respectively, and in the control group 48.1% and 63.9%, respectively, with a significant difference between groups （P〈0.01）. Hematoma volume decreased significantly at day 7 of treatment in the treatment group than the control group （P=0.038）. Average Barthel scores in the treatment group after treatment was 89.11 ＋ 19.93, and in the control group 82.18 ＋ 24.02 （P=0.003）. NIHSS scores of the two groups after treatment decreased significantly compared with before treatment （P=0.001）. Patient-reported outcomes in the treatment group were lower than the control group at day 21 and 3 months of treatment （P〈0.05）. There were 4 deaths, 2 in each group, and 11 adverse events, 6 in the treatment group and 5 in the control group. Conclusion： The integrative therapy combined TRABC with conventional Western treatment for HICH could promote hematoma absorption thus minimize neurologic impairment, without increasing intracerebral hematoma expansion and re-bleeding.
